Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key

Feb 27 2020

• By Cathy Kelly

SC1901_Novartis logo_751955164 _1200.jpg — A Closer Look At Novartis' US Market Acess Plan For Inclisiran

Related Content

Humana Medicare Advantage Plans Targeting Hemlibra, Herceptin Hylecta With Step Therapy

Mar 02 2020

Humana Jumps In: Medicare Part B Step Therapy Program Includes Cancer Drugs

Jan 30 2019

Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar

Nov 13 2019

Novartis Sees Reimbursement Advantage For PCSK9 Launch

Nov 25 2019

Related Companies

Novartis AG

Humana Inc.

UnitedHealth Group

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Bayer AG

Genentech, Inc.

Additional Topics

United States Reimbursement Cost Effectiveness Commercial BioPharmaceutical

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.